New drug combo aims to shrink liver cancer tumors in the lungs
NCT ID NCT07482670
First seen Mar 24, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This study tests whether combining two drugs (camrelizumab and rivoceranib) with or without local treatments like surgery or radiation can shrink tumors in people with advanced liver cancer that has spread to the lungs. About 32 adults aged 18 to 85 with this condition will take part. The main goal is to see how many patients respond to treatment and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATECELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.